Navigation Links
FDA Approves New Treatment for Rare Type of Pancreatic Cancer
Date:5/6/2011

SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).  

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.

"Patients with this cancer have few effective treatment options," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Afinitor has demonstrated the ability to slow the growth and spread of neuroendocrine tumors of the pancreas."

The safety and effectiveness of Afinitor was established in a clinical trial in 410 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease.  Patients in the study were selected to receive Afinitor or placebo (sugar pill). The trial was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).

In patients treated with Afinitor, the median length of time they lived without the cancer spreading or worsening was 11 months compared with 4.6 months in patients who received placebo.  Patients who received placebo were able to receive Afinitor if their disease worsened.  

In patients treated with Afinitor for neuroendocrine pancreatic tumors, the most commonly reported side effects included inflammation of the mouth (stomatitis), rash, diarrhea, fatigue, swelling (edema), stomach (abdominal) pain, nausea, fever, and headache.

Afinitor is also approved to treat patients with ki
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  Luminex Corporation (NASDAQ: LMNX ) today ... 30, 2014. Financial and operating highlights include the following: ... million, a 2 percent increase over the second quarter ... $8.3 million, a 9 percent increase over the second ... 268 multiplexing analyzers, which included 148 LX systems, 96 ...
(Date:7/28/2014)... 2014 /PRNewswire-iReach/ -- June 28 th , 2014 – Oncolab, ... the AMAS cancer test, is making its AACC debut (booth ... test, which is a serum-based in vitro immunoassay, has been ... significant tool in the fight against cancer recurrence. ... estimated 17 million cancer survivors in the US alone, the ...
(Date:7/28/2014)...  Air Products (NYSE: APD ) understands ... vital to any healthcare facility. This understanding has driven ... the efficiency of its oxygen supply systems, but also ... systems for emergency oxygen supply and high ... the 51 st ASHE Annual Conference & ...
Breaking Medicine Technology:Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3
... BOSTON, Feb. 16, 2011 MedAptus®, the market ... New England Baptist Hospital (NEBH) has selected the ... inpatient medicine providers. The NEBH hospitalist team, comprised ... MedAptus, Inpatient Edition via the web as well ...
... Feb. 15, 2011 Warner Chilcott plc (Nasdaq: WCRX ... full year 2010 financial results prior to the market opening on ... a press release, the Company will host a conference call for ... (Eastern Time) to review the results. To participate in the call, ...
Cached Medicine Technology:Hospitalists at New England Baptist Hospital Choose MedAptus 2
(Date:7/28/2014)... 2014 Ticket Down is reliable ... in Dallas, TX at the Cotton Bowl. The 2014 ... USA and it is an eight team tourney. The ... including teams from La Liga, Serie A, English Premier League, ... it out on the pitch include: Manchester United, Manchester ...
(Date:7/28/2014)... 2014 Cape Regional Medical Center, ... technology solution in an effort to streamline ... collaboration with their New Jersey health information exchange ... located in New Jersey, serves the local population ... variety of inpatient and outpatient services. With a ...
(Date:7/28/2014)... (HealthDay News) -- British researchers report that an alternative ... around. In their experiments, the scientists found that ... one person to the other than what is known ... exchange might suffice as a cultural substitute for the ... in the August issue of the American Journal ...
(Date:7/28/2014)... SIMpalm helped its client to launch ... on iTunes for download . Experience a new way ... you to listen and cook along with expert real-time audio ... out the ingredients and equipment, press play, and follow the ... ahead of time, just relax and cook along with us. ...
(Date:7/28/2014)... LA JOLLAWhen you,re expecting somethinglike the meal you,ve ... interest, unique electrical rhythms sweep through your brain. ... and they reflect a symphony of cellsboth excitatory ... their role has been debated, gamma waves have ... in the patterns have been tied to schizophrenia, ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
... ... warning concerning the osteoporosis drug Fosamax as The Sanders Firm prepares for the first ... ... States Food and Drug Administration, via its website at FDA.gov , has issued ...
... the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of dental treatment during pregnancy and ensure women the services they need. , ... , ... ... ...
... ... same HCG diet that doctors are charging thousands of dollars for. , ... (PRWEB) March 15, 2010 -- YourHCG.com ... plans. YourHCG.com has helped over 50,000 people lose weight for about 10% of what the ...
... MISSISSAUGA, ON , March 15 /PRNewswire-FirstCall/ - Nuvo ... on the research and development of drug products that are ... transdermal drug delivery technologies, and on the development of its ... enrolled the first patient in its European Phase 2 clinical ...
... eight times more likely to die, study finds , MONDAY, March ... hip are five to eight times more likely to die in ... Belgian researchers has found. , And, while the death rate after ... the break, it never returns to the death rate seen in ...
... link between obesity and disease has been well documented. There,s ... as they,ve shown in the United States at least 90,000 ... of Alberta researcher Richard Lamb is on his way to ... the scientific process works. Lamb is studying a cell ...
Cached Medicine News:Health News:The Sanders Firm is Assigned the First Fosamax Trial 2Health News:The Sanders Firm is Assigned the First Fosamax Trial 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:YourHCG.com Changes the Way People Lose Weight by Offering an Affordable HCG Diet Plan 2Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 2Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 3Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 5Health News:Risk of Death Persists After a Hip Fracture 2Health News:Risk of Death Persists After a Hip Fracture 3
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
... Scoliosis Brace™ for neuromuscular scoliosis ... lightweight, soft, and easy to ... comfort. The Soft Boston ... non-cracking orthopedic grade copolymer and ...
Medicine Products: